On February 14, 2008, Zoll, Kranz and Borgess, LLC was the first law firm in the nation to file suit against Baxter Healthcare Corporation and other related companies regarding contaminated batches of its drug, Heparin. We lead the way with multiple cases filed in federal court and performed investigations into cases both in and outside Ohio.
On May 29, 2008, Zoll, Kranz and Borgess, LLC argued before the United States Judicial Panel on Multi-District Litigation that the Heparin Products Liability Litigation be transferred to the Northern District of Ohio, located in Toledo, Ohio, before the Honorable Chief Judge James G. Carr. Other districts, including the Southern District of Illinois, District of New Jersey, Southern District of Florida, the District of Puerto Rico, and the Northern District of California, were suggested by Baxter Healthcare Corp., Scientific Protein Laboratories, LLC, and other parties.
On June 6, 2008, the United States Judicial Panel on Multi-District Litigation issued a transfer order, transferring the Heparin Multi-District Litigation MDL No. 1953 to the Northern District of Ohio, before the Honorable Chief Judge James G. Carr. To obtain a copy of this order, CLICK HERE.
Our law firm was also honored when three of our clients, Leroy Hubley, Colleen Hubley and Johanna Staples, were invited by the U.S. House Commerce Committee on Energy and Commerce, one of the oldest standing committees of the U.S. House of Representatives, to speak on April 29, 2008, at a hearing entitled, “The Heparin Disaster: Chinese Counterfeits and American Failures.”
Panel I included witnesses David Nelson, Senior Investigator for the Committee on Energy and Commerce; Collen Hubley, Leroy Hubley and Johanna Marie Staples
Panel II witnesses included Janet Woodcock, Director of the FDA’s Center for Drug Evaluation and Research; Deborah M. Autor, Director of FDA’s Office of Compliance; and Regina T. Brown, Consumer Safter Officer of the FDA’s Division of Field Investigations.
Panels III and IV included witnesses Robert Parkinson, CEO and President of Baxter International, Inc.; David Strunce, CEO of Scientific Protein Laboratories; Yan Wang, Ph.D. Vice President of Business Development and Research at Scientific Protein Laboratories; and Clive Meanwell, CEO of The Medicines Co.
In addition, to view the written statements submitted by Leroy Hubley, Colleen Hubley, Johanna Staples or other witnesses, please click on their name below.
David Nelson, Senior Investigator for the Committee on Energy and Commerce
Janet Woodcock, Director of the FDA’s Center for Drug Evaluation
Robert Parkinson, CEO and President of Baxter International, Inc.
David Strunce, CEO of Scientific Protein Laboratories
Clive Meanwell, CEO of The Medicines Co.
Additional information regarding the recall of contaminated heparin and subsequent litigation can be obtained by clicking on the links below:
Overview of the Heparin Recall and the Contaminant
Allegations in the Lawsuits Filed by Zoll, Kranz & Borgess, LLC